TotalMarketCap

Fate Therapeutics

FATENasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$225.862 M

$1.89 -9.81%

Close of 6 Nov 2026

As of 6 Nov 2026, Fate Therapeutics (FATE) has a market capitalization of $225.9M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$6.65M

#3209 by revenue

Earnings

-$136.3M

Loss-making

Shares outstanding

121,568,755

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #90Lineage Cell TherapeuticsLCTX$247.3M
  2. #91Lexeo TherapeuticsLXEO$239.6M
  3. #92Fate TherapeuticsFATE$225.9M
  4. #93Cabaletta BioCABA$214.5M
  5. #94Protalix BioTherapeuticsPLX$202.6M

What if Fate Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$235,659.76

Per share 125,018× higher

Bitcoin $1.53T

$12,751.14

Per share 6,765× higher

Apple $5.02T

$41,860.80

Per share 22,207× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Fate Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.